sodium 2-methyl-3-[(5-methyl-1,3-thiazol-2-yl)carbamoyl]-1,1-dioxo-2H-1λ6,2-benzothiazin-4-olate hydrate

• ChemBase ID: 133726
• Molecular Formular: C14H14N3NaO5S2
• Molecular Mass: 391.39783
• Monoisotopic Mass: 391.02725684
• SMILES: Cc1cnc(s1)NC(=O)C1=C(c2ccccc2S(=O)(=O)N1C)[O-].O.[Na+]
• Canonical SMILES: Cc1cnc(s1)NC(=O)C1=C([O-])c2ccccc2S(=O)(=O)N1C.O.[Na+]
• InChI: InChI=1S/C14H13N3O4S2.Na.H2O/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2;;/h3-7,18H,1-2H3,(H,15,16,19);;1H2/q;+1;/p-1
• InChIKey: IZBZAOZGNNQKPJ-UHFFFAOYSA-M

NAMES AND DATABASE IDS

Names

• IUPAC name: sodium 2-methyl-3-[(5-methyl-1,3-thiazol-2-yl)carbamoyl]-1,1-dioxo-2H-1λ^6,2-benzothiazin-4-olate hydrate
• IUPAC Traditional name: sodium 2-methyl-3-[(5-methyl-1,3-thiazol-2-yl)carbamoyl]-1,1-dioxo-1λ^6,2-benzothiazin-4-olate hydrate
• Synonyms: 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide sodium hydrate; Metacam sodium salt hydrate; Mobec sodium salt hydrate; UH-AC 62XX sodium salt hydrate; Meloxicam sodium salt hydrate

Database IDs

• CAS Number: 71125-39-8(anhydrous)
• MDL Number: MFCD11046047
• PubChem SID: 24278802; 162228003
• PubChem CID: 23702962

CALCULATED PROPERTIES

• Acid pKa: 4.47116
• H Acceptors: 5
• H Donor: 1
• LogD (pH = 5.5): 0.53962874
• LogD (pH = 7.4): -0.97548914
• Log P: 1.6005814
• Molar Refractivity: 99.1752 cm^3
• Polarizability: 32.875427 Å^3
• Polar Surface Area: 102.43 Å^2
• Rotatable Bonds: 2
• Lipinski's Rule of Five: true

PROPERTIES

Physical Property

• Solubility: DMSO: soluble; H2O: soluble
• Apperance: yellow

Safety Information

• European Hazard Symbols: Harmful (Xn)
• UN Number: 2811
• German water hazard class: 3
• Hazard Class: 6.1
• Packing Group: 3
• Risk Statements: 22-36/37/38
• Safety Statements: 26
• RID/ADR: UN 2811 6.1/PG 3

DETAILS

Sigma Aldrich - M3935

Biochem/physiol Actions
Meloxicam, a member of the oxicam family, is a non-steroidal anti-inflammatory drug (NSAID) that shows 300-fold selectivity for cyclooxygenase-2 (COX-2) vs cyclooxygenase-1 (COX-1). Meloxicam has been shown to abolish thymulin-induced increases of cytokines and NGF in the liver of rats. Meloxicam also suppresses tumor growth and may be capable of antagonizing cachexia in vitro.